LMR Partners’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.54M | Buy |
+31,672
| New | +$2.61M | 0.01% | 807 |
|
|
2025
Q4 | – | Sell |
-6,887
| Closed | -$536K | – | 1588 |
|
|
2025
Q3 | $536K | Buy |
+6,887
| New | +$538K | ﹤0.01% | 1080 |
|
|
2025
Q2 | – | Sell |
-97,472
| Closed | -$7.06M | – | 1467 |
|
|
2025
Q1 | $7.06M | Sell |
97,472
-36,171
| -27% | -$2.59M | 0.07% | 321 |
|
|
2024
Q4 | $9.89M | Buy |
+133,643
| New | +$9.35M | 0.08% | 250 |
|
|
2024
Q2 | – | Sell |
-86,648
| Closed | -$8.28M | – | 1161 |
|
|
2024
Q1 | $8.28M | Buy |
+86,648
| New | +$7.28M | 0.08% | 217 |
|
|
2022
Q4 | – | Sell |
-9,103
| Closed | -$752K | – | 1160 |
|
|
2022
Q3 | $752K | Sell |
9,103
-7,738
| -46% | -$745K | 0.01% | 803 |
|
|
2022
Q2 | $1.6M | Buy |
+16,841
| New | +$1.74M | 0.03% | 595 |
|
|
2021
Q4 | – | Sell |
-2,163
| Closed | -$245K | – | 1188 |
|
|
2021
Q3 | $245K | Sell |
2,163
-16,445
| -88% | -$1.88M | ﹤0.01% | 903 |
|
|
2021
Q2 | $1.93M | Buy |
18,608
+11,096
| +148% | +$1.05M | 0.03% | 385 |
|
|
2021
Q1 | $628K | Buy |
+7,512
| New | +$635K | 0.02% | 580 |
|
|
2020
Q3 | – | Sell |
-9,610
| Closed | -$664K | – | 515 |
|
|
2020
Q2 | $664K | Buy |
+9,610
| New | +$683K | 0.02% | 398 |
|
|
2020
Q1 | – | Sell |
-39,579
| Closed | -$3.08K | – | 307 |
|
|
2019
Q4 | $3.08K | Buy |
+39,579
| New | +$3.09M | 0.01% | 100 |
|
|
2019
Q3 | – | Sell |
-25,953
| Closed | -$1.6M | – | 448 |
|
|
2019
Q2 | $1.6M | Buy |
+25,953
| New | +$1.57M | 0.06% | 159 |
|
|
2019
Q1 | – | Sell |
-20,658
| Closed | -$1.05M | – | 396 |
|
|
2018
Q4 | $1.05M | Buy |
+20,658
| New | +$1.05M | 0.05% | 175 |
|
|
2018
Q3 | – | Sell |
-13,524
| Closed | -$656K | – | 404 |
|
|
2018
Q2 | $656K | Buy |
13,524
+7,728
| +133% | +$361K | 0.03% | 222 |
|
|
2018
Q1 | $218K | Hold |
5,796
| – | – | 0.02% | 299 |
|
|
2017
Q4 | $218K | Sell |
5,796
-13,383
| -70% | -$491K | 0.02% | 299 |
|
|
2017
Q3 | $698K | Sell |
19,179
-27,057
| -59% | -$1.03M | 0.08% | 148 |
|
|
2017
Q2 | $1.82M | Buy |
+46,236
| New | +$1.69M | 0.11% | 188 |
|
|
2017
Q1 | – | Sell |
-55,791
| Closed | -$1.74M | – | 392 |
|
|
2016
Q4 | $1.74M | Sell |
55,791
-4,866
| -8% | -$158K | 0.27% | 77 |
|
|
2016
Q3 | $2.44M | Sell |
60,657
-66,462
| -52% | -$2.5M | 0.23% | 92 |
|
|
2016
Q2 | $4.23M | Buy |
127,119
+67,218
| +112% | +$2.3M | 0.65% | 20 |
|
|
2016
Q1 | $1.76K | Buy |
59,901
+4,866
| +9% | +$134K | 0.19% | 98 |
|
|
2015
Q4 | $1.45M | Buy |
55,035
+5,019
| +10% | +$130K | 0.47% | 39 |
|
|
2015
Q3 | $1.19M | Sell |
50,016
-53,514
| -52% | -$1.29M | 0.13% | 161 |
|
|
2015
Q2 | $2.46M | Buy |
103,530
+8,604
| +9% | +$194K | 0.3% | 77 |
|
|
2015
Q1 | $2.25M | Sell |
94,926
-25,134
| -21% | -$564K | 0.31% | 92 |
|
|
2014
Q4 | $2.55M | Buy |
120,060
+101,076
| +532% | +$2.03M | 0.33% | 69 |
|
|
2014
Q3 | $323K | Sell |
18,984
-117,924
| -86% | -$1.86M | 0.03% | 210 |
|
|
2014
Q2 | $1.96M | Buy |
136,908
+119,658
| +694% | +$1.62M | 0.16% | 166 |
|
|
2014
Q1 | $213K | Buy |
+17,250
| New | +$199K | 0.03% | 219 |
|
Other funds holding EW
VCM
VPM
LMR Partners's EW Position: Q1 2026 in Review
LMR Partners opened a new position in Edwards Lifesciences (EW) in Q1 2026: 31,672 shares worth $2.54M. The stake represents 0.01% of the portfolio and ranks #807 among its holdings. This is a return to the name: LMR Partners previously reported a position in EW as recently as Q3 2025.
LMR Partners first reported a position in EW in Q1 2014 and has held it in 31 quarters since. The position peaked at $9.89M in Q4 2024. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- LMR Partners held 31,672 shares of Edwards Lifesciences worth $2.54M as of Q1 2026.
- Edwards Lifesciences was a new LMR Partners position in Q1 2026.
- Edwards Lifesciences made up 0.01% of LMR Partners's portfolio in Q1 2026, its #807 holding.
- LMR Partners first reported a position in Edwards Lifesciences in Q1 2014 and has held it in 31 quarters since.
- LMR Partners's Edwards Lifesciences position peaked at $9.89M in Q4 2024.
- 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.